中国药房2025，Vol.36Issue(9)：1141-1146,6.DOI:10.6039/j.issn.1001-0408.2025.09.21
替尔泊肽用于2型糖尿病和长期体重管理的快速卫生技术评估
Rapid health technology assessment of tirzepatide for diabetes mellitus type 2 and long-term weight management
摘要
Abstract
OBJECTIVE To evaluate the efficacy,safety and cost-effectiveness of tirzepatide for diabetes mellitus type 2(T2DM)and long-term weight management,and provide evidence-based basis for clinical drug treatment and health insurance policy formulation.METHODS Computer searches were conducted in Embase,PubMed,the Cochrane Library,CNKI and health technology assessment(HTA)official website from their inception to October 1st 2024 to collect HTA report,systematic review/meta-analysis and pharmacoeconomic study on tirzepatide for the treatment of T2DM or for weight management.After data extraction and quality evaluation,descriptive analysis was performed on the research results.RESULTS Totally 18 papers were included,including 14 systematic reviews/meta-analyses and 4 pharmacoeconomics studies,and no HTA report was retrieved.In terms of efficacy,most results showed that the tirzepatide 10 mg and 15 mg were significantly better than other glucagon-like peptide-1(GLP-1)receptor agonists in reducing glycosylated hemoglobin,body weight,and waist circumference(P＜0.05).In terms of safety,compared with other GLP-1 receptor agonists,tirzepatide did not increase the incidence of gastrointestinal-related adverse events(AE),the incidence of AE of grade≥3,or the incidence of severe hypoglycemia(P＞0.05).However,tirzepatide 15 mg may significantly increased the incidence of hypoglycemia and the rate of discontinuation due to adverse reactions(P＜0.05).In terms of cost-effectiveness,based on the background of foreign pharmacoeconomic studies,tirzepatide was more cost-effective compared to semaglutide and liraglutide in the treatment of T2DM or for weight management.CONCLUSIONS Tirzepatide at doses of 10 mg and 15 mg has good efficacy and safety for the treatment of T2DM and for long-term weight management.However,when using the 15 mg dose of tirzepatide,close monitoring is required due to the risk of hypoglycemia and discontinuation due to adverse reactions it may pose.Based on pharmacoeconomic studies conducted abroad results,tirzepatide exhibits economic advantages.关键词
替尔泊肽/2型糖尿病/肥胖/快速卫生技术评估Key words
tirzepatide/diabetes mellitus type 2/obesity/rapid health technology assessment分类
医药卫生引用本文复制引用
谢泽宇,刘一诺,梁焯茹,曹耀华,郑桂梅,曹伟灵..替尔泊肽用于2型糖尿病和长期体重管理的快速卫生技术评估[J].中国药房,2025,36(9):1141-1146,6.基金项目
广东省医院药学"真实世界证据与临床用药卫生技术评估"专项课题(No.2024-0808-03) （No.2024-0808-03）
深圳市医疗卫生三名工程项目(No.SZSM202301035) （No.SZSM202301035）
